Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.
Location: United States
Employees: 11-50
Total raised: $347M
Founded date: 2019
Investors 3
| Date | Name | Website |
| 23.03.2023 | Avoro Capi... | avorocapit... |
| 15.03.2023 | Access Bio... | accessbio-... |
| - | RA Capital... | racap.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.10.2025 | Series C | $157M | HealthCap |
| 22.02.2023 | Series B | $135M | - |
| 22.07.2021 | Series A | $55M | Novo Holdi... |
Mentions in press and media 16
| Date | Title | Description |
| 28.10.2025 | Hemab Therapeutics Secures $157M for Breakthrough Bleeding Disorder Therapies | Hemab Therapeutics closed a $157 million Series C funding round. The clinical-stage biotechnology firm targets severe, underserved bleeding and thrombotic disorders. This significant capital influx will accelerate two flagship programs: HMB... |
| 27.10.2025 | Hemab Therapeutics Nets $157 Million Series C Financing | CAMBRIDGE, MA, Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced the completion of a multifold oversubscribed $157 mi... |
| 27.10.2025 | Hemab Therapeutics Raises $157M in Series C Financing | Hemab Therapeutics, a Cambridge, MA, and Copenhagen, Denmark-based clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, closed a $157m Series C financing... |
| 27.10.2025 | Hemab Therapeutics: $157 Million Series C Secured For Advancing Treatments For Underserved Bleeding Disorders | Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious bleeding and thrombotic disorders, announced that it has completed a $157 million Series C financing. The oversubscribed fundi... |
| 20.06.2024 | Denmark: Europe's hub for tech innovation and collaboration | Denmark's tech ecosystem thrives on innovation, collaboration, and sustainability. Centered in Copenhagen, it supports a diverse range of sectors including biotechnology, renewable energy, and digital innovation. The city's vibrant startup ... |
| 03.03.2023 | Hemab Therapeutics’ Statement Announcing the Planned Departure of Co-Founder and CTO Johan Faber | COPENHAGEN, Demark and BOSTON, March 1, 2023 Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today issued the following s... |
| 22.02.2023 | HealthCap Portfolio Company Hemab Therapeutics raises $135M Series B Financing | HealthCap VIII portfolio company Hemab Therapeutics today announced the closing of an oversubscribed $135 million Series B financing. The round was led by Access Biotechnology with participation from new investors Deep Track Capital, Avoro ... |
| 21.02.2023 | Hemab Therapeutics Raises $135M in Series B Financing | Hemab Therapeutics, a Copenhagen, Denmark and Boston, MA-based clinical-stage biotechnology company developing prophylactic therapeutics for bleeding and thrombotic disorders, raised $135M in Series B funding. The round was led by Access Bi... |
| 21.02.2023 | Hemab Therapeutics Announces $135M Series B | BOSTON, MA, Hemab Therapeutics today announced the closing of an oversubscribed $135 million Series B financing. >> Click here for more funding data on Hemab Therapeutics >> To export Hemab Therapeutics funding data to PDF a... |
| 11.01.2023 | Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia | Bispecific antibody HMB-001 positioned as the first prophylactic treatment for rare bleeding disorders CEO Benny Sorensen, MD, PhD, delivered the update during a corporate overview presented at the 41st Annual JP Morgan Healthcare Conferen... |
Show more